| Code | CSB-RA023978MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to NBL-020, targeting TNFRSF1B (Tumor Necrosis Factor Receptor Superfamily Member 1B), also known as TNFR2 or CD120b. TNFRSF1B is a cell surface receptor that binds tumor necrosis factor-alpha (TNF-α) and plays a critical role in immune regulation, inflammation, and cell survival signaling. Unlike TNFRSF1A, which primarily mediates pro-inflammatory and apoptotic responses, TNFRSF1B predominantly activates anti-apoptotic pathways and supports regulatory T cell function. This receptor is implicated in various autoimmune disorders, chronic inflammatory conditions, and cancer, where its expression on tumor cells and immunosuppressive cells can promote tumor progression and immune evasion.
The reference antibody NBL-020 has been utilized in research investigating TNFR2 biology and its role in immune modulation. This biosimilar provides researchers with a reliable tool for exploring TNFRSF1B-mediated signaling pathways, evaluating its therapeutic potential in inflammatory diseases and oncology, and investigating immune checkpoint mechanisms. The antibody supports diverse experimental approaches in immunology and cancer biology research.
There are currently no reviews for this product.